In the oncology overview, you’ll learn, among other essential insights:

• How different kinds of plans will use comparative effectiveness research to make coverage decisions
• How payers are planning to work with oncology-focused accountable care organizations to limit spending
• How payers are adopting – or avoiding – reimbursement innovations from UnitedHealth, specifically targeting high-cost Part B therapies
• How plans are exploiting quality reporting initiatives to contain costs
• The growing influence of NCCN guidelines in blocking off-label prescribing
• How plans are requiring – or avoiding – diagnostic-directed prescribing in their reimbursement decisions
• The report then focuses on payer responses to specific products in four key tumor types. The report directly addresses the following indications and respective marketed and late development stage agents: